Director, Coagulation Laboratory Hosp University PA
Hematology
Dr. Douglas B. Cines, MD
|
|
Give Review
Douglas Cines practices Hematology. He went to medical school at NYU School of Medicine. He received 1 awards: "Elected Member". Douglas Cines is a published MD. He published 99 publications, including: 'Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).'
Publications
- Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).
- Platelet transactivation by monocytes promotes the prothrombotic state in heparin-induced thrombocytopenia.
- α-Defensins induce a post-translational modification of LDL that promotes atherosclerosis at normal levels of plasma cholesterol.
- Can Immune Thrombocytopenia Be Cured with Medical Therapy?
- Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents murine models of thrombotic thrombocytopenic purpura.
- Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
- T2 Magnetic Resonance: A Diagnostic Platform for Studying Integrated Hemostasis in Whole Blood-Proof of Concept.
- Pathogenesis of immune thrombocytopenia.
- Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin.
- Bad (or good) things come in small packages.
- PAI-1-Derived Peptide EEIIMD Prevents Hypoxia/Ischemia-Induced Aggravation of Endothelin- and Thromboxane-Induced Cerebrovasoconstriction.
- tPA-S(481)A Prevents Impairment of Cerebrovascular Autoregulation by Endogenous tPA after Traumatic Brain Injury by Upregulating p38 MAPK and Inhibiting ET-1.
- TMA: beware of complements.
- Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.
- Multifunctional roles of Urokinase Plasminogen Activator (uPA) in Cancer Stemness and in Chemo-resistance of Pancreatic Cancer.
- Advanced drug delivery systems for anti-thrombotic agents.
- Protamine-induced thrombocytopenia?
- Novel diagnostic assays for heparin-induced thrombocytopenia.
- Antigen and substrate withdrawal in the management of autoimmune thrombotic Disorders.
- Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypoten...
- Quantitative analysis of thrombomodulin-mediated conversion of protein C to APC: Translation from in vitro to in vivo.
- Avoiding intuxication.
- Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.
- Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia.
- tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury.
- RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothromb...
- How I treat heparin-induced thrombocytopenia (HIT).
- Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.
- Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice.
- tPA regulates pulmonary vascular activity through NMDA receptors.
- Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.
- Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-depe...
- Glucagon protects against impaired NMDA-mediated cerebrovasodilation and cerebral autoregulation during hypotension after brain injury by activating cAMP protein kinas...
- Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils.
- Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.
- Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1.
- Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiati...
- Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.
- PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.
- Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
- Induction of tissue factor by urokinase in lung epithelial cells and in the lungs.
- Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier.
- Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.
- International consensus report on the investigation and management of primary immune thrombocytopenia.
- Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?
- Immune thrombocytopenia.
- The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation.
- Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.
- Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.
- Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK M...
- The ITP syndrome: pathogenic and clinical diversity.
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
- Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.
- uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.
- Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury.
- Pathobiology of secondary immune thrombocytopenia.
- Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK.
- Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.
- Nuclear translocation of urokinase-type plasminogen activator.
- Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.
- Determinants of PF4/heparin immunogenicity.
- Pathogenesis of chronic immune thrombocytopenic purpura.
- A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP).
- Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots a...
- The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
- Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
- Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
- Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury.
- Urokinase induces activation of STAT3 in lung epithelial cells.
- Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.
- Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
- LRP and alphavbeta3 mediate tPA activation of smooth muscle cells.
- Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
- Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
- Structure of human urokinase plasminogen activator in complex with its receptor.
- Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysi...
- Inhibition of pathologic retinal neovascularization by alpha-defensins.
- How I treat idiopathic thrombocytopenic purpura (ITP).
- Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig.
- PF4/heparin complexes are T cell-dependent antigens.
- Blood clearance and activity of erythrocyte-coupled fibrinolytics.
- Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity.
- Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.
- Management of adult idiopathic thrombocytopenic purpura.
- Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.
- Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury.
- Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis.
- Interactions of platelet factor 4 with the vessel wall.
- Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils.
- Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor.
- Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
- Congenital and acquired thrombocytopenia.
- Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura.
- The kringle stabilizes urokinase binding to the urokinase receptor.
- Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
- Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.
- Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
- Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells.
Schools
New York University School Of Medicine
Nc Meml Hospital University Nc
Hospital Of The University Of Pennsylvania
Conditions Treated
- Anemia
- Coagulation Disorders (incl. Hemophilia)
- Neutropenia
- Pancytopenia
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Elected Member
Education
-
University of Pennsylvania Health System -
University of North Carolina Hospitals -
NYU School of Medicine
Hospital
-
Hospital of the University of Pennsylvania -
Pennsylvania Hospital -
Penn Presbyterian Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Anthony P. Scarpaci, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alina E. Dulau Florea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Efrat Dotan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew B. Dancis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shannon A. Carty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence F. Brass, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Allison M. Zibelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Selina Luger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James K. Mangan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Courtney D. Dinardo, MD |
|
|
Dr. Tami Bach, MD
This Doctor is OpenDoctor Recommended.
|